medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2022, Número 1

<< Anterior Siguiente >>

Rev Biomed 2022; 33 (1)


Utilidad del ultrasonido versus biopsia en el diagnóstico de metástasis a ganglio centinela en pacientes con cáncer de mama

Armas M, Brito-Núñez N

Idioma: Español
Referencias bibliográficas: 36
Paginas: 4-11
Archivo PDF: 116.96 Kb.


RESUMEN

Introducción. El ultrasonido del ganglio centinela puede ser útil en la detección temprana de metástasis de mama.
Objetivo. Comparar la utilidad del ultrasonido versus biopsia de ganglio centinela en el diagnóstico de metástasis a ganglio centinela en pacientes con cáncer de mama.
Materiales y Métodos. Se realizó un estudio retrospectivo, observacional, comparativo y de corte transversal en un grupo de 148 pacientes con cáncer de mama atendidas en la clínica de prevención de la Sociedad Anticancerosa de Venezuela enero 2018 y diciembre 2020.
Resultados. Se encontró una mayor cantidad de casos con metástasis ganglionar en aquellos con edad mayor de 40 años (83.1%). El carcinoma ductal infiltrante fue el tipo más frecuentemente encontrado (83.8% [n=119], p=0.3). La concordancia diagnóstica del ultrasonido preoperatorio para el diagnóstico correcto de un ganglio centinela fue de 0.28 que de acuerdo a la escala de Kappa es aceptable (p=0.001). Tomando a la biopsia como el estándar de oro, el correcto diagnóstico del ganglio centinela por ultrasonido fue de 66.4% con un intervalo de confianza al 95% (IC95%) de 57.7 a 74.2%, la sensibilidad fue de 47.3% (IC95%, 33.9-61.1%), la especificidad de 79.7% (IC95%, 68.9%-87.5%), el valor predictivo positivo fue de 61.9% (IC95%, 45.6%-76.0%) y el valor predictivo negativo fue de 68.5% (IC95%, 57.8%-77.5%).
Conclusión. El ultrasonido tiene una utilidad aceptable en el diagnóstico de metástasis a ganglio centinela.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Veronesi U., Paganelli G., Viale G., Luini A., Zurrida S., Galimberti V., et al. A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer. N Engl J Med. 2003;349(6):546–53, https://doi.org/10.1056/NEJMoa012782.

  2. Lyman GH., Giuliano AE., Somerfield MR., Benson AB., Bodurka DC., Burstein HJ., et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. J Clin Oncol. 2005;23(30):7703–20, https://doi. org/10.1200/JCO.2005.08.001.

  3. Krag DN., Weaver DL., Alex JC., Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335–40, https://doi.org/10.1016/0960- 7404(93)90064-6.

  4. Chu KU., Turner RR., Hansen NM., Brennan MB., Giuliano AE. Sentinel Node Metastasis in Patients with Breast Carcinoma Accurately Predicts Immunohistochemically Detectable Nonsentinel Node Metastasis. Ann Surg Oncol. 1999;6(8):756–61, https:// doi.org/10.1007/s10434-999-0756-2.

  5. Kamath VJ. Characteristics of the Sentinel Lymph Node in Breast Cancer Predict Further Involvement of Higher- Echelon Nodes in the Axilla. Arch Surg. 2001;136(6):688, https://doi.org/10.1001/archsurg.136.6.688.

  6. Benson JR., Querci della Rovere G. Management of the axilla in women with breast cancer. The Breast. 2007;16(2):130–6, https://doi.org/10.1016/j. breast.2006.06.003.

  7. Duff M., Hill ADK., McGreal G., Walsh S., McDermott EW., O’Higgins NJ. Prospective evaluation of the morbidity of axillary clearance for breast cancer. Br J Surg. 2001;88(1):114–7, https://doi.org/10.1046/j.1365- 2168.2001.01620.x.

  8. Giuliano AE., Ballman K., McCall L., Beitsch P., Whitworth PW., Blumencranz P., et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. Ann Surg. 2016;128(3):12–21, https://doi.org/10.1097/SLA.0b013e3181f08f32.

  9. Giuliano AE., McCall L., Beitsch P., Whitworth PW., Blumencranz P., Leitch AM., et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. Trans . Meet Am Surg Assoc. 2010;128:12–21, https://doi.org/10.1097/ SLA.0b013e3181f08f32.

  10. Giuliano AE. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA. 2011;305(6):569, https://doi.org/10.1001/jama.2011.90.

  11. Cools-Lartigue J., Meterissian S. Accuracy of Axillary Ultrasound in the Diagnosis of Nodal Metastasis in Invasive Breast Cancer: A Review. World J Surg. 2012;36(1):46–54, https://doi.org/10.1007/s00268-011- 1319-9.

  12. Ibrahim-Zada I., Grant CS., Glazebrook KN., Boughey JC. Preoperative Axillary Ultrasound in Breast Cancer: Safely Avoiding Frozen Section of Sentinel Lymph Nodes in Breast-Conserving Surgery. J Am Coll Surg. 2013;217(1):7–15, https://doi.org/10.1016/j. jamcollsurg.2013.01.064.

  13. Houssami N., Ciatto S., Turner RM., Cody HS., Macaskill P. Preoperative Ultrasound-Guided Needle Biopsy of Axillary Nodes in Invasive Breast Cancer. Ann Surg. 2011;254(2):243–51, https://doi.org/10.1097/ SLA.0b013e31821f1564.

  14. Reynders A., Brouckaert O., Smeets A., Laenen A., Yoshihara E., Persyn F., et al. Prediction of nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. The Breast. 2014;23(4):453–9, https://doi.org/10.1016/j. breast.2014.03.009.

  15. Chung A., Gangi A., Mirocha J., Giuliano A. Applicability of the ACOSOG Z0011 Criteria in Women with High- Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery. Ann Surg Oncol. 2015;22(4):1128– 32, https://doi.org/10.1245/s10434-014-4090-y.

  16. Van Zee KJ., Manasseh D-ME., Bevilacqua JLB., Boolbol SK., Fey J V., Tan LK., et al. A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy. Ann Surg Oncol. 2003;10(10):1140–51, https:// doi.org/10.1245/ASO.2003.03.015.

  17. Kohrt HE., Olshen RA., Bermas HR., Goodson WH., Wood DJ., Henry S., et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8(1):66, https://doi. org/10.1186/1471-2407-8-66.

  18. Pal A., Provenzano E., Duffy SW., Pinder SE., Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95(3):302–9, https:// doi.org/10.1002/bjs.5943.

  19. Goldhirsch A., Ingle JN., Gelber RD., Coates AS., Thürlimann B., Senn H-J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol. 2009;20(8):1319–29, https:// doi.org/10.1093/annonc/mdp322.

  20. Cserni G., Boross G., Maráz R., Leidenius MHK., Meretoja TJ., Heikkila PS., et al. Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer. Surg Oncol. 2012;21(2):59– 65, https://doi.org/10.1016/j.suronc.2011.12.001.

  21. Coutant C., Olivier C., Lambaudie E., Fondrinier E., Marchal F., Guillemin F., et al. Comparison of Models to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: A Prospective Multicenter Study. J Clin Oncol. 2009;27(17):2800–8, https://doi.org/10.1200/ JCO.2008.19.7418.

  22. Meretoja TJ., Leidenius MHK., Heikkilä PS., Boross G., Sejben I., Regitnig P., et al. International Multicenter Tool to Predict the Risk of Nonsentinel Node Metastases in Breast Cancer. JNCI J Natl Cancer Inst. 2012;104(24):1888–96, https://doi.org/10.1093/jnci/ djs455.

  23. Wasif N. Underuse of Axillary Dissection for the Management of Sentinel Node Micrometastases in Breast Cancer. Arch Surg. 2010;145(2):161, https://doi. org/10.1001/archsurg.2009.269.

  24. Hansen NM., Grube B., Ye X., Turner RR., Brenner RJ., Sim M-S., et al. Impact of Micrometastases in the Sentinel Node of Patients With Invasive Breast Cancer. J Clin Oncol. 2009;27(28):4679–84, https://doi. org/10.1200/JCO.2008.19.0686.

  25. Galimberti V., Botteri E., Chifu C., Gentilini O., Luini A., Intra M., et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2012;131(3):819–25, https://doi. org/10.1007/s10549-011-1486-2.

  26. Montagna E., Viale G., Rotmensz N., Maisonneuve P., Galimberti V., Luini A., et al. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat. 2009;118(2):385– 94, https://doi.org/10.1007/s10549-009-0446-6.

  27. Gentilini O., Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: entinel node vs bservation after axillary ltraSou ). The Breast. 2012;21(5):678–81, https://doi. org/10.1016/j.breast.2012.06.013.

  28. Kim GR., Choi JS., Han B-K., Lee JE., Nam SJ., Ko EY., et al. Preoperative Axillary US in Early-Stage Breast Cancer: Potential to Prevent Unnecessary Axillary Lymph Node Dissection. Radiology. 2018;288(1):55– 63, https://doi.org/10.1148/radiol.2018171987.

  29. Rukanskienė D., Veikutis V., Jonaitienė E., Basevičiūtė M., Kunigiškis D., Paukštaitienė R., et al. Preoperative Axillary Ultrasound versus Sentinel Lymph Node Biopsy in Patients with Early Breast Cancer. Medicina (B Aires). 2020;56(3):127, https://doi.org/10.3390/ medicina56030127.

  30. Reimer T., Stachs A., Nekljudova V., Loibl S., Hartmann S., Wolter K., et al. Restricted Axillary Staging in Clinically and Sonographically Node- Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup- Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd. 2017;77(02):149–57, https://doi. org/10.1055/s-0042-122853.

  31. Arguedas-Arguedas O. Tipos de diseño en estudios de investigación Biomédica. Acta Méd Costarric. 2010;52(1):16–8.

  32. Romero Mares PI. Tecnicas de Muestreo I. Departamento de Probabilidad y Estadística IIMAS UNAM. Available at: http://www.dpye.iimas.unam.mx/patricia/muestreo/ notas/intro.pdf. Accessed October 1, 2018.

  33. Abraira V. El índice kappa. Semer - Med Fam. 2001;27(5):247–9, https://doi.org/10.1016/S1138- 3593(01)73955-X.

  34. Chang JM., Leung JWT., Moy L., Ha SM., Moon WK. Axillary Nodal Evaluation in Breast Cancer: State of the Art. Radiology. 2020;295(3):500–15, https://doi. org/10.1148/radiol.2020192534.

  35. Bedi DG., Krishnamurthy R., Krishnamurthy S., Edeiken BS., Le-Petross H., Fornage BD., et al. Cortical Morphologic Features of Axillary Lymph Nodes as a Predictor of Metastasis in Breast Cancer: In Vitro Sonographic Study. Am J Roentgenol. 2008;191(3):646– 52, https://doi.org/10.2214/AJR.07.2460.

  36. Vidalle D., Calcagno F., Rodríguez L., Lucena M., Crocco C. Rendimiento de la ecografía axilar en cáncer de mama. Rev Argentina Mastología. 2019;38(140):10– 8.




2020     |     www.medigraphic.com